Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Catheter Associated Urinary Tract Infections Treatment Market Outlook (2023 to 2033)

According to Future Market Insights research, during the projected period, the global catheter associated urinary tract infections treatment market is expected to grow at a CAGR of 3.0%. The market value is projected to increase from US$ 1.31 Billion in 2023 to US$ 1.76 Billion by 2033. The catheter associated urinary tract infections treatment market was valued at US$ 1.26 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 3.9% in 2023.

Attributes Details
Market Size (2023) US$ 1.31 Billion
Projected Market Value (2033) US$ 1.76 Billion
Global Market Growth Rate (2023 to 2033) 3.0% CAGR
Market Share of Top 5 Countries 52.1%

As assessed by Future Market Insights, among the drug type, quinolones held a market share of around 37.6% in the global market, in 2022. In 2022, the catheter associated urinary tract infections treatment market sales accounted for a revenue share of 72.3% in the global complicated UTI market, which was valued at around US$ 1.8 Billion.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 4.1% in the last 5 years from 2017 to 2022.

Catheter associated urinary tract infections (CAUTIs) are common complications associated with use of the catheters. Elderly individuals are more susceptible to UTIs due to weakened immune systems, and urinary retentions. Moreover, individuals with compromised immune systems such as those with diabetics, or undergoing immunosuppressive therapy are at increased risk of UTIs.

These infections may also reoccur more frequently due to the body’s reduced ability to fight off the infection.

  • According to the National Library of Medicine - 2019, Urinary tract infections (UTIs) are the most common outpatient infections, with a lifetime incidence of 50−60% in adult women.
  • According to the National Library of Medicine - 2019, In younger women, increased sexual activity is a major risk factor for UTIs and recurrence within 6 months is common.

The growth of catheter associated urinary tract infections treatment market is due to the growing number of UTIs and recurrent UTIs. This has led to a higher demand for effective treatment choices.

What are the Factors Influencing the Demand for Catheter Associated Urinary Tract Infections Treatment?

The increasing prevalence of CAUTIs worldwide can be attributed to a variety of factors, including prolonged catheter use, inadequate catheter care and hygiene and other factors.

Patients may require catheterization for a prolonged time due to various medical conditions. Prolonged catheter use increases the opportunity for bacteria to colonise the urinary tract and cause infection. Proper maintenance and care of the urinary catheters are essential for the reduction of the infection.

Hence, the global catheter associated urinary tract infections treatment market is been driven by the high prevalence and incidence rate of the disease worldwide.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Can the Market Growth Be Affected in Any Way?

The demand for new treatment arises from the need to address antibiotic-resistant CAUTIs. As bacteria become resistant to traditional antibiotics, it becomes harder to treat these infections efficiently. This increases the risk of the implication and prolonged hospital stays for patients and adds a financial burden on the healthcare system due to the increased cost of treating drug-resistant infections.

  • According to a study conducted by the University of Minnesota on March 22, 2023, it indicates that pathogens that cause catheter-associated urinary tract infections (CAUTIs) are more resistant to antibiotics than pathogens that do not cause CAUTIs.
  • Based on research conducted by the University of Minnesota on March 22 2023, the rate of resistance to commonly prescribed antibiotics such as ciprofloxacin, norfloxacin, and trimethoprim-sulfamethoxazole ranges between 13 and 31 percent.

The prevalence of antibiotic-resistant CAUTIs is a significant concern as it limits the effectiveness of traditional antibiotic therapy. Moreover, the development of new antibiotics is slow and costly, and the pipeline for novel antibiotics is relatively dry. Moreover, this can be a significant factor affecting the growth of the CAUTIs market.

Country-wise Insights

What Factors are likely to drive the USA Market Forward?

The USA accounted for around 18.2% market share in the global market in 2022. The USA market’s growth is expected to rise at an overall CAGR of 2.2% over the forecast period.

Urinary tract infection is one of the most frequent infectious diseases caused by bacteria. A complicated urinary tract infection can affect anyone, regardless of gender or age, and they are caused by anatomical or functional abnormalities in the urinary system.

  • According to an article published by the National Library of Medicine on May 2, 2019, between 50% and 60% of adult women will encounter at least one UTI in their lifetime, while about 10% of postmenopausal women reported having a UTI in the previous year.

An increase in chronic illness such as diabetes, and kidney disease, such as renal failure and bladder cancer, is driving the usage of catheters and other drainage devices among patients and the increased use of indwelling use of urinary catheters is the attributing factor in the rise of complicated UTIs. Complicated UTIs are generally more challenging to treat compared to uncomplicated UTIs, as they are associated with more severe symptoms and have a higher risk of complication.

These are the major factors that help the market grow exponentially in the U.S., region.

Why India Market is Dominating Global Urinary Tract Infections Treatment Market?

The India market held around 10.2 % market share of the global market in 2022.

The large patient population in India is one of the reasons why the Indian market has a significant presence in the global catheter associated urinary tract infections treatment market.

With such a large population, the incidence and prevalence of CAUTIs are also higher.

  • According to an article published by the Department of Economic and Social Affairs on April 2023, the current population of India is about 1.42 Billion.

Since CAUTI is a common healthcare-associated infection, the large patient population in India creates a high demand for CAUTIs treatment.

What are the Factors Contributing to High Demand for Catheter Associated Urinary Tract Infections Treatment in China?

China held a market share of about 9.5% of the global market in 2022.

The Chinese government to improve healthcare outcomes and reduce healthcare-associated infections, including CAUTIs, has implemented several measures and programs.

The promotion of awareness and education regarding infection prevention measures is one significant initiative. The aim is to increase awareness among healthcare providers and patients about the risk associated with CAUTIs and the importance of preventing the infection.

The government provides training and education to healthcare providers to enhance their knowledge and skills in preventing CAUTIs. Additionally, they focus on this effort. In addition, supporting the adoption of infection prevention measures in healthcare facilities. China is in demand for the market of catheter-associated urinary tract infections.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Why Drug Type is leading in the Global Market?

The Quinolones sub-segment held around 37.6% share of the global market in 2022 within the drug type.

Quinolones have a broad-spectrum antimicrobial activity. In addition, Gram-negative organism commonly causes CAUTIs, and quinolones have demonstrated efficacy against these pathogens. In addition, quinolones have the ability to achieve high concentration in the urine, which is desirable for treating urinary tract infections.

Quinolones also have good penetration in the tissue of the urinary tract, including the bladder wall, renal parenchyma and prostate gland.

They are also available in both oral and intravenous formulations providing convenience and flexibility in the treatment of CAUTIs.

Which Indication Type has a higher share within the Global Market?

The Asymptomatic CAUTI (Bacteriuria) segment held around 58.9% share of the total market in 2022 within the indication type.

In comparison to symptomatic CAUTIs, asymptomatic CAUTIs are more common. Many patients with urinary catheters may not exhibit common infection symptoms, such as fever or pain, making it difficult to detect these infections without specialized testing.

The greater prevalence of asymptomatic CAUTIs contributes to its dominant position in the indication type segment.

Which Service Provider Propels the Global Sales in the Market?

Retail pharmacies hold a share of about 43.2% in 2022, within the global market.

Medication used in the treatment of CAUTIs is mainly distributed through retail pharmacies, which serve as the main distribution hubs. To ensure that patients have access to necessary antibiotics and other relevant drugs, they make sure that these medications are available.

In retail settings, pharmacists and pharmacy staff offer education and counselling to patients about the correct use of medication for CAUTIs. These are the services provided by them. Retail pharmacies offer a variety of over-the-counter products that can assist in managing CAUTIs in addition to the prescribed medication.

Competition Landscape

The treatment market for catheter-associated urinary tract infections treatment is competitive. In addition to expanding their presence in emerging markets through new partnerships and merger acquisitions, market leaders are concentrating on the introduction of technologically advanced products. The competitive environment includes an analysis of a handful of global and local corporations that control the majority of the market share. In addition to acquisitions, mergers, and partnerships with key market participants.

Some key instances of development include:

  • In June 2019, it was announced by Merck that a definitive agreement has been entered into with Tilos Therapeutics for the development of drugs to treat cancer, fibrosis, and autoimmune diseases.
  • In November 2018, Allergan announced that the FDA has accepted the Supplemental New Drug Application for Avycaz to treat patients with Complicated Urinary Tract Infections (CUTI) and Complicated Intra-Abdominal Infections (CIAI).

Similarly, the team at Future Market Insights has tracked recent developments related to companies in the catheter associated urinary tract infections treatment market, which are available in the full report.

Catheter Associated Urinary Tract Infections Treatment Industry Report Scope

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2017 to 2022
Market Analysis USD Million for Value
Key Regions Covered North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa.
Key Countries Covered USA, Canada, Brazil, Argentina, Mexico, Germany, France, UK, Italy, Spain, Russia, BENELUX, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, Türkiye, GCC Countries, Northern Africa, and South Africa
Key Market Segments Covered Drug Type, Indication, Distribution Channel and Region
Key Companies Covered
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Bayer AG
  • Johnson & Johnson
  • Novartis International AG
  • Sanofi
  • Roche Holding AG
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Boehringer Ingelheim
  • Daiichi Sankyo Company, Limited
  • Gilead Sciences, Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
Report Coverage Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing Available upon Request

Key Segments Covered in Urinary Tract Infections Treatment Industry Research

Drug Type:

  • Penicillin & Combinations
    • Amoxicillin
    • Amoxicillin+ Clavulanate Potassium
    • Others
  • Quinolones
    • Ciprofloxacin
    • Levofloxacin
    • Nalidixic acid
    • Norfloxacin
    • Others
  • Cephalosporin
    • Ceftriaxone
    • Cefuroxime
    • Cefixime
    • Cephalexin
  • Aminoglycoside Antibiotics
    • Amikacin
    • Gentamicin
  • Sulphonamides (Sulfamethoxazole +Trimethoprim)
  • Azoles and Amphotericin B
  • Tetracycline (Doxycycline)
  • Nitrofurans (Nitrofurantoin)
  • Other

Indication Type:

  • Asymptomatic CAUTI (Bacteriuria)
  • Symptomatic CAUTI (Bacteremic)

Distribution Channel:

  • Hospital Pharmacies
  • Gynaecology and Urology Clinics
  • Drug Stores
  • Retail Pharmacies
  • Online Drug Stores

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Catheter Associated Urinary Tract Infections Treatment Market Size in 2023?

The market is expected to be valued at US$ 1.31 billion in 2023.

Who are the Prominent Catheter Associated Urinary Tract Infections Treatment Market Players?

AstraZeneca, Bayer AG, and Sanofi are the key market players.

What Factors are likely to Drive the United States Market Forward?

Increased prevalence of chronic illnesses like diabetes drives catheter usage.

Which Service Provider Propels the Global Sales in the Market?

Retail pharmacies hold a share of about 43.2% in 2022.

What is the Projected Size of the Market by 2033?

The market is estimated to reach US$ 1.76 billion by 2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Value Added Insights

    4.1. Product Adoption Analysis

    4.2. Product USP Analysis

    4.3. Pipeline Analysis

    4.4. Regulatory Landscape, By Country

    4.5. UTI Antibiotic Treatment Cycle

    4.6. PESTLE Analysis

    4.7. Porter’s Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global Pharmaceutical Outlook

        5.1.2. Global Healthcare Expenditure

        5.1.3. Global R&D Expenditure

        5.1.4. Global Complicated UTI Market Outlook (Parent Market Outlook)

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Technological Advancements

        5.2.2. Top Companies Historical Growth

        5.2.3. Entry of Top Companies

        5.2.4. Prevalence of CAUTIs

        5.2.5. Focus on Infection Prevention

        5.2.6. Aging Population and Healthcare Demographics

        5.2.7. Regulatory Policies and Guidelines

        5.2.8. Technological Advancements and Innovation

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033

    6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022

    6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

    6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Type 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Million) Trends Analysis By Drug Type, 2017 to 2022

    7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        7.3.1. Penicillin & Combinations

            7.3.1.1. Amoxicillin

            7.3.1.2. Amoxicillin+ Clavulanate Potassium

            7.3.1.3. Others

        7.3.2. Quinolones

            7.3.2.1. Ciprofloxacin

            7.3.2.2. Levofloxacin

            7.3.2.3. Nalidixic acid

            7.3.2.4. Norfloxacin

            7.3.2.5. Others

        7.3.3. Cephalosporin

            7.3.3.1. Ceftriaxone

            7.3.3.2. Cefuroxime

            7.3.3.3. Cefixime

            7.3.3.4. Cephalexin

        7.3.4. Aminoglycoside Antibiotics

            7.3.4.1. Amikacin

            7.3.4.2. Gentamicin

        7.3.5. Sulphonamides (Sulfamethoxazole +Trimethoprim)

        7.3.6. Azoles and Amphotericin B

        7.3.7. Tetracycline (Doxycycline)

        7.3.8. Nitrofurans (Nitrofurantoin)

        7.3.9. Other

    7.4. Market Attractiveness Analysis By Drug Type

8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Trends Analysis By Indication, 2017 to 2022

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        8.3.1. Asymptomatic CAUTI (Bacteriuria)

        8.3.2. Symptomatic CAUTI (Bacteremic)

    8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Trends Analysis By Distribution Channel, 2017 to 2022

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        9.3.1. Hospital Pharmacies

        9.3.2. Gynecology and Urology Clinics

        9.3.3. Drug Stores

        9.3.4. Retail Pharmacies

        9.3.5. Online Drug Stores

    9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Million) Trend Analysis By Region, 2017 to 2022

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America Analysis 2017 to 2022 and Forecast 2023 to 2033

    11.1. Introduction

    11.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017 to 2022 Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. U.S.

            11.2.1.2. Canada

        11.2.2. By Drug Type

        11.2.3. Indication

        11.2.4. Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. Indication

        11.3.4. Distribution Channel

    11.4. Market Trends

    11.5. Key Market Participants - Intensity Mapping

    11.6. Drivers and Restraints - Impact Analysis

    11.7. Country Level Analysis & Forecast

        11.7.1. U.S. Market Analysis

            11.7.1.1. Introduction

            11.7.1.2. Market Analysis and Forecast By Market Taxonomy

                11.7.1.2.1. By Drug Type

                11.7.1.2.2. By Indication

                11.7.1.2.3. By Distribution Channel

        11.7.2. Canada Market Analysis

            11.7.2.1. Introduction

            11.7.2.2. Market Analysis and Forecast By Market Taxonomy

                11.7.2.2.1. By Drug Type

                11.7.2.2.2. By Indication

                11.7.2.2.3. By Distribution Channel

12. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017 to 2022

    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        12.3.1. By Country

            12.3.1.1. Mexico

            12.3.1.2. Brazil

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Drug Type

        12.3.3. By Indication

        12.3.4. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug Type

        12.4.3. By Indication

        12.4.4. By Distribution Channel

    12.5. Market Trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country Level Analysis & Forecast

        12.8.1. Mexico Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast By Market Taxonomy

                12.8.1.2.1. By Drug Type

                12.8.1.2.2. By Indication

                12.8.1.2.3. By Distribution Channel

        12.8.2. Brazil Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast By Market Taxonomy

                12.8.2.2.1. By Drug Type

                12.8.2.2.2. By Indication

                12.8.2.2.3. By Distribution Channel

        12.8.3. Argentina Market Analysis

            12.8.3.1. Introduction

            12.8.3.2. Market Analysis and Forecast By Market Taxonomy

                12.8.3.2.1. By Drug Type

                12.8.3.2.2. By Indication

                12.8.3.2.3. By Distribution Channel

13. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Million)  Trend Analysis By Market Taxonomy, 2017 to 2022

    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By Drug Type

        13.3.3. By Indication

        13.3.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug Type

        13.4.3. By Indication

        13.4.4. By Distribution Channel

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. Germany Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast By Market Taxonomy

                13.8.1.2.1. By Drug Type

                13.8.1.2.2. By Indication

                13.8.1.2.3. By Distribution Channel

        13.8.2. Italy Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast By Market Taxonomy

                13.8.2.2.1. By Drug Type

                13.8.2.2.2. By Indication

                13.8.2.2.3. By Distribution Channel

        13.8.3. France Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast By Market Taxonomy

                13.8.3.2.1. By Drug Type

                13.8.3.2.2. By Indication

                13.8.3.2.3. By Distribution Channel

        13.8.4. U.K. Market Analysis

            13.8.4.1. Introduction

            13.8.4.2. Market Analysis and Forecast By Market Taxonomy

                13.8.4.2.1. By Drug Type

                13.8.4.2.2. By Indication

                13.8.4.2.3. By Distribution Channel

        13.8.5. Spain Market Analysis

            13.8.5.1. Introduction

            13.8.5.2. Market Analysis and Forecast By Market Taxonomy

                13.8.5.2.1. By Drug Type

                13.8.5.2.2. By Indication

                13.8.5.2.3. By Distribution Channel

        13.8.6. Russia Market Analysis

            13.8.6.1. Introduction

            13.8.6.2. Market Analysis and Forecast By Market Taxonomy

                13.8.6.2.1. By Drug Type

                13.8.6.2.2. By Indication

                13.8.6.2.3. By Distribution Channel

        13.8.7. BENELUX Market Analysis

            13.8.7.1. Introduction

            13.8.7.2. Market Analysis and Forecast By Market Taxonomy

                13.8.7.2.1. By Drug Type

                13.8.7.2.2. By Indication

                13.8.7.2.3. By Distribution Channel

14. East Asia Analysis 2017 to 2022 and Forecast 2023 to 2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Million)  Trend Analysis By Market Taxonomy, 2017 to 2022

    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        14.3.1. By Country

            14.3.1.1. China

            14.3.1.2. Japan

            14.3.1.3. South Korea

        14.3.2. By Drug Type

        14.3.3. By Indication

        14.3.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug Type

        14.4.3. By Indication

        14.4.4. By Distribution Channel

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. China Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast By Market Taxonomy

                14.8.1.2.1. By Drug Type

                14.8.1.2.2. By Indication

                14.8.1.2.3. By Distribution Channel

        14.8.2. Japan Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast By Market Taxonomy

                14.8.2.2.1. By Drug Type

                14.8.2.2.2. By Indication

                14.8.2.2.3. By Distribution Channel

        14.8.3. South Korea Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast By Market Taxonomy

                14.8.3.2.1. By Drug Type

                14.8.3.2.2. By Indication

                14.8.3.2.3. By Distribution Channel

15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Indonesia

            15.3.1.3. Malaysia

            15.3.1.4. Thailand

            15.3.1.5. Rest of South Asia

        15.3.2. By Drug Type

        15.3.3. By Indication

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug Type

        15.4.3. By Indication

        15.4.4. By Distribution Channel

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. India Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast By Market Taxonomy

                15.8.1.2.1. By Drug Type

                15.8.1.2.2. By Indication

                15.8.1.2.3. By Distribution Channel

        15.8.2. Indonesia Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast By Market Taxonomy

                15.8.2.2.1. By Drug Type

                15.8.2.2.2. By Indication

                15.8.2.2.3. By Distribution Channel

        15.8.3. Malaysia Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast By Market Taxonomy

                15.8.3.2.1. By Drug Type

                15.8.3.2.2. By Indication

                15.8.3.2.3. By Distribution Channel

        15.8.4. Thailand Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast By Market Taxonomy

                15.8.4.2.1. By Drug Type

                15.8.4.2.2. By Indication

                15.8.4.2.3. By Distribution Channel

16. Oceania Market 2017 to 2022 and Forecast 2023-2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017 to 2022

    16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        16.3.1. By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Drug Type

        16.3.3. By Indication

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug Type

        16.4.3. By Indication

        16.4.4. By Distribution Channel

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. Australia Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast By Market Taxonomy

                16.8.1.2.1. By Drug Type

                16.8.1.2.2. By Indication

                16.8.1.2.3. By Distribution Channel

        16.8.2. New Zealand Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast By Market Taxonomy

                16.8.2.2.1. By Drug Type

                16.8.2.2.2. By Indication

                16.8.2.2.3. By Distribution Channel

17. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    17.1. Introduction

    17.2. Pricing Analysis

    17.3. Historical Market Size (US$ Million)  Trend Analysis By Market Taxonomy, 2017 to 2022

    17.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        17.4.1. By Country

            17.4.1.1. GCC Countries

            17.4.1.2. Türkiye

            17.4.1.3. Northern Africa

            17.4.1.4. South Africa

            17.4.1.5. Rest of Middle East and Africa

        17.4.2. By Drug Type

        17.4.3. By Indication

        17.4.4. By Distribution Channel

    17.5. Market Attractiveness Analysis

        17.5.1. By Country

        17.5.2. By Drug Type

        17.5.3. By Indication

        17.5.4. By Distribution Channel

    17.6. Market Trends

    17.7. Key Market Participants - Intensity Mapping

    17.8. Drivers and Restraints - Impact Analysis

    17.9. Country Level Analysis & Forecast

        17.9.1. GCC Countries Market Analysis

            17.9.1.1. Introduction

            17.9.1.2. Market Analysis and Forecast By Market Taxonomy

                17.9.1.2.1. By Drug Type

                17.9.1.2.2. By Indication

                17.9.1.2.3. By Distribution Channel

        17.9.2. Türkiye Market Analysis

            17.9.2.1. Introduction

            17.9.2.2. Market Analysis and Forecast By Market Taxonomy

                17.9.2.2.1. By Drug Type

                17.9.2.2.2. By Indication

                17.9.2.2.3. By Distribution Channel

        17.9.3. Northern Africa Market Analysis

            17.9.3.1. Introduction

            17.9.3.2. Market Analysis and Forecast By Market Taxonomy

                17.9.3.2.1. By Drug Type

                17.9.3.2.2. By Indication

                17.9.3.2.3. By Distribution Channel

        17.9.4. South Africa Market Analysis

            17.9.4.1. Introduction

            17.9.4.2. Market Analysis and Forecast By Market Taxonomy

                17.9.4.2.1. By Drug Type

                17.9.4.2.2. By Indication

                17.9.4.2.3. By Distribution Channel

18. Market Structure Analysis

    18.1. Market Analysis By Tier of Companies

    18.2. Market Share Analysis of Top Players

    18.3. Market Concentration

    18.4. Market Presence Analysis

        18.4.1. Regional Footprint Analysis

        18.4.2. Product Footprint Analysis

        18.4.3. Channel Footprint Analysis

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Branding and Promotional Strategies, By Key Players

    19.3. Key Development Analysis

    19.4. Competition Deep Dive

        19.4.1. Pfizer

            19.4.1.1. Overview

            19.4.1.2. Product Portfolio

            19.4.1.3. Sales Footprint

            19.4.1.4. Key Developments

            19.4.1.5. SWOT Analysis

            19.4.1.6. Strategy Overview

                19.4.1.6.1. Marketing Strategies

                19.4.1.6.2. Product Strategies

                19.4.1.6.3. Channel Strategies

        19.4.2. Merck & Co., Inc.

            19.4.2.1. Overview

            19.4.2.2. Product Portfolio

            19.4.2.3. Sales Footprint

            19.4.2.4. Key Developments

            19.4.2.5. SWOT Analysis

            19.4.2.6. Strategy Overview

                19.4.2.6.1. Marketing Strategies

                19.4.2.6.2. Product Strategies

                19.4.2.6.3. Channel Strategies

        19.4.3. GlaxoSmithKline (GSK)

            19.4.3.1. Overview

            19.4.3.2. Product Portfolio

            19.4.3.3. Sales Footprint

            19.4.3.4. Key Developments

            19.4.3.5. SWOT Analysis

            19.4.3.6. Strategy Overview

                19.4.3.6.1. Marketing Strategies

                19.4.3.6.2. Product Strategies

                19.4.3.6.3. Channel Strategies

        19.4.4. AstraZeneca

            19.4.4.1. Overview

            19.4.4.2. Product Portfolio

            19.4.4.3. Sales Footprint

            19.4.4.4. Key Developments

            19.4.4.5. SWOT Analysis

            19.4.4.6. Strategy Overview

                19.4.4.6.1. Marketing Strategies

                19.4.4.6.2. Product Strategies

                19.4.4.6.3. Channel Strategies

        19.4.5. Bayer AG

            19.4.5.1. Overview

            19.4.5.2. Product Portfolio

            19.4.5.3. Sales Footprint

            19.4.5.4. Key Developments

            19.4.5.5. SWOT Analysis

            19.4.5.6. Strategy Overview

                19.4.5.6.1. Marketing Strategies

                19.4.5.6.2. Product Strategies

                19.4.5.6.3. Channel Strategies

        19.4.6. Johnson & Johnson

            19.4.6.1. Overview

            19.4.6.2. Product Portfolio

            19.4.6.3. Sales Footprint

            19.4.6.4. Key Developments

            19.4.6.5. SWOT Analysis

            19.4.6.6. Strategy Overview

                19.4.6.6.1. Marketing Strategies

                19.4.6.6.2. Product Strategies

                19.4.6.6.3. Channel Strategies

        19.4.7. Novartis International AG

            19.4.7.1. Overview

            19.4.7.2. Product Portfolio

            19.4.7.3. Sales Footprint

            19.4.7.4. Key Developments

            19.4.7.5. SWOT Analysis

            19.4.7.6. Strategy Overview

                19.4.7.6.1. Marketing Strategies

                19.4.7.6.2. Product Strategies

                19.4.7.6.3. Channel Strategies

        19.4.8. Sanofi

            19.4.8.1. Overview

            19.4.8.2. Product Portfolio

            19.4.8.3. Sales Footprint

            19.4.8.4. Key Developments

            19.4.8.5. SWOT Analysis

            19.4.8.6. Strategy Overview

                19.4.8.6.1. Marketing Strategies

                19.4.8.6.2. Product Strategies

                19.4.8.6.3. Channel Strategies

        19.4.9. Roche Holding AG

            19.4.9.1. Overview

            19.4.9.2. Product Portfolio

            19.4.9.3. Sales Footprint

            19.4.9.4. Key Developments

            19.4.9.5. SWOT Analysis

            19.4.9.6. Strategy Overview

                19.4.9.6.1. Marketing Strategies

                19.4.9.6.2. Product Strategies

                19.4.9.6.3. Channel Strategies

        19.4.10. Eli Lilly and Company

            19.4.10.1. Overview

            19.4.10.2. Product Portfolio

            19.4.10.3. Sales Footprint

            19.4.10.4. Key Developments

            19.4.10.5. SWOT Analysis

            19.4.10.6. Strategy Overview

                19.4.10.6.1. Marketing Strategies

                19.4.10.6.2. Product Strategies

                19.4.10.6.3. Channel Strategies

        19.4.11. Bristol-Myers Squibb Company

            19.4.11.1. Overview

            19.4.11.2. Product Portfolio

            19.4.11.3. Sales Footprint

            19.4.11.4. Key Developments

            19.4.11.5. SWOT Analysis

            19.4.11.6. Strategy Overview

                19.4.11.6.1. Marketing Strategies

                19.4.11.6.2. Product Strategies

                19.4.11.6.3. Channel Strategies

        19.4.12. Abbott Laboratories

            19.4.12.1. Overview

            19.4.12.2. Product Portfolio

            19.4.12.3. Sales Footprint

            19.4.12.4. Key Developments

            19.4.12.5. SWOT Analysis

            19.4.12.6. Strategy Overview

                19.4.12.6.1. Marketing Strategies

                19.4.12.6.2. Product Strategies

                19.4.12.6.3. Channel Strategies

        19.4.13. Astellas Pharma Inc.

            19.4.13.1. Overview

            19.4.13.2. Product Portfolio

            19.4.13.3. Sales Footprint

            19.4.13.4. Key Developments

            19.4.13.5. SWOT Analysis

            19.4.13.6. Strategy Overview

                19.4.13.6.1. Marketing Strategies

                19.4.13.6.2. Product Strategies

                19.4.13.6.3. Channel Strategies

        19.4.14. Boehringer Ingelheim

            19.4.14.1. Overview

            19.4.14.2. Product Portfolio

            19.4.14.3. Sales Footprint

            19.4.14.4. Key Developments

            19.4.14.5. SWOT Analysis

            19.4.14.6. Strategy Overview

                19.4.14.6.1. Marketing Strategies

                19.4.14.6.2. Product Strategies

                19.4.14.6.3. Channel Strategies

        19.4.15. Daiichi Sankyo Company, Limited

            19.4.15.1. Overview

            19.4.15.2. Product Portfolio

            19.4.15.3. Sales Footprint

            19.4.15.4. Key Developments

            19.4.15.5. SWOT Analysis

            19.4.15.6. Strategy Overview

                19.4.15.6.1. Marketing Strategies

                19.4.15.6.2. Product Strategies

                19.4.15.6.3. Channel Strategies

        19.4.16. Gilead Sciences, Inc.

            19.4.16.1. Overview

            19.4.16.2. Product Portfolio

            19.4.16.3. Sales Footprint

            19.4.16.4. Key Developments

            19.4.16.5. SWOT Analysis

            19.4.16.6. Strategy Overview

                19.4.16.6.1. Marketing Strategies

                19.4.16.6.2. Product Strategies

                19.4.16.6.3. Channel Strategies

        19.4.17. Mylan N.V.

            19.4.17.1. Overview

            19.4.17.2. Product Portfolio

            19.4.17.3. Sales Footprint

            19.4.17.4. Key Developments

            19.4.17.5. SWOT Analysis

            19.4.17.6. Strategy Overview

                19.4.17.6.1. Marketing Strategies

                19.4.17.6.2. Product Strategies

                19.4.17.6.3. Channel Strategies

        19.4.18. Teva Pharmaceutical Industries Ltd.

            19.4.18.1. Overview

            19.4.18.2. Product Portfolio

            19.4.18.3. Sales Footprint

            19.4.18.4. Key Developments

            19.4.18.5. SWOT Analysis

            19.4.18.6. Strategy Overview

                19.4.18.6.1. Marketing Strategies

                19.4.18.6.2. Product Strategies

                19.4.18.6.3. Channel Strategies

        19.4.19. Sun Pharmaceutical Industries Ltd.

            19.4.19.1. Overview

            19.4.19.2. Product Portfolio

            19.4.19.3. Sales Footprint

            19.4.19.4. Key Developments

            19.4.19.5. SWOT Analysis

            19.4.19.6. Strategy Overview

                19.4.19.6.1. Marketing Strategies

                19.4.19.6.2. Product Strategies

                19.4.19.6.3. Channel Strategies

        19.4.20. Lupin Limited

            19.4.20.1. Overview

            19.4.20.2. Product Portfolio

            19.4.20.3. Sales Footprint

            19.4.20.4. Key Developments

            19.4.20.5. SWOT Analysis

            19.4.20.6. Strategy Overview

                19.4.20.6.1. Marketing Strategies

                19.4.20.6.2. Product Strategies

                19.4.20.6.3. Channel Strategies

20. Assumptions and Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Urinary Tract Infection (UTI) Treatment Market

Published : January 2024

Healthcare

Uncomplicated Urinary Tract Infection Treatment Market

Published : April 2023

Healthcare

Urinary Retention Therapeutics Market

Published : January 2023

Explore Healthcare Insights

View Reports

Catheter Associated Urinary Tract Infections (UTI) Treatment Market